Versatility of Different Pharmaceutical Formulations of Hydromorphone in the Management of Severe Cancer Pain and Pain in Palliative Care

• Junker U , LuxEA, NeugebauerEA, BaslerHD. Therapy of pain in multimorbid elderly patients. Med. Monatsschr. Pharm.32 , 175–181 (2009).
   PubMedGoogle Scholar
• Bonica JJ . Evolution and current status of pain programs. J. Pain Symptom Manage.5 , 368–374 (1990).
   PubMedGoogle Scholar
• Twycross RG . The fight against cancer pain. Ann. Oncol.5 , 111–112 (1994).
   PubMed Web of Science ®Google Scholar
• WHO. Cancer Pain Relief. With a Guide to Opioid Availability (2nd Edition). WHO, Geneva, Switzerland (1996).
   Google Scholar
• Caraceni A , HanksG, KaasaS et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 13 , e58–e68 (2012).
   PubMed Web of Science ®Google Scholar
• Caraceni A , PigniA, BrunelliC. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat. Med.25 , 402–409 (2010).
   Web of Science ®Google Scholar
• Pipam W , LikarR, KlockerJ et al. Results of a poll of cancer patients with respect to pain and quality of life. Schmerz 16 , 481–489 (2002).
   PubMed Web of Science ®Google Scholar
• Sohn W . Hydromorphon – ein starkes Opioid mit Vorteilen bei der Verstoffwechselung. MMW Fortschr. Med.2 , 51–55 (2003).
   Google Scholar
• Moriarty M , McDonaldCJ, MillerAJ. A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J. Clin. Res.2 , 1–8 (1999).
   Google Scholar
• Davis MP , McPhersonML. Tabling hydromorphone: do we have it right?J. Palliat. Med.13(4) , 365–366 (2010).
   PubMed Web of Science ®Google Scholar
• Wirz S , WartenbergHC, NadstawekJ. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Cancer16 , 999–1009 (2008).
   PubMed Web of Science ®Google Scholar
• Pergolizzi J , BögerRH, BuddK et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 8 , 287–313 (2008).
   PubMedGoogle Scholar
• Klaschik E . Schmerztherapie und Symptomkontrolle in der Palliativmedizin. In: Palliativmedizin. Husebö S, Klaschik E (Eds). 3 Auflage, Springer, Berlin, Germany. 181–277 (2003).
   Google Scholar
• Kloke M , WeberM, HanekopGG. Tumorschmerztherapie im Zeichen der evidenz-basierten Medizin. Onkologe8 , S44–S46 (2002).
   Google Scholar
• de Stoutz ND , BrueraE, Suarez-AlmazorM. Opioid rotation for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage.10(5) , 378–384 (1995).
   PubMed Web of Science ®Google Scholar
• Clemens K , KlaschikE. Morphin und Hydromorphon bei Palliativpatienten mit Niereninsuffizienz. Anästh. Intensive Med.50 , 70–76 (2009).
   Web of Science ®Google Scholar
• Lee MA , LengMEF, TiernanEJJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat. Med.15 , 26–34 (2001).
   PubMed Web of Science ®Google Scholar
• Thwaites D , McCannS, BroderickP. Hydromorphone neuroexcitation. J. Palliat. Med.7 , 545–550 (2004).
   PubMedGoogle Scholar
• Foley KM . Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs6(Suppl. 3) , S4–S13 (1995).
   PubMedGoogle Scholar
• Niscola P , ScaramucciL, VischiniG et al. The use of major analgesics in patients with renal dysfunction. Curr. Drug Targets 11(6) , 752–758 (2010).
   PubMed Web of Science ®Google Scholar
• Ashby M , FlemingB, WoodM, SomogyiA. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J. Pain Symptom Manage.14 , 157–167 (1997).
   PubMed Web of Science ®Google Scholar
• Dubs A , WiedemeierP, CaduffB. Morphin-Intoxikation bei chronischer Niereninsuffizienz. Morphin-6-glucuronid als pharmakologisch aktiver Morphin-Metabolit. Dtsch Med. Wschr.124 , 896–898 (1999).
   PubMed Web of Science ®Google Scholar
• Sohn W . Zuverlässige Schmerzlinderung und Verbesserung der Lebensqualität bei multimorbiden, älteren Patienten. Retardiertes Hydromorphon in der ambulanten Schmerztherapie. Med. Welt.10 , 504–507 (2007).
   Google Scholar
• Nadstawek J , WartenbergHC, SchenkM, WirzSR. Hydromorphone in elderly patients with polypathia and with severe pain. Pain Clin.18(5–6) , 403–413 (2006).
   Google Scholar
• Junker U , FiggeV. Retardiertes Hydromorphon bei älteren Patienten mit starken Schmerzen unterschiedlicher Ätiologie. MMW Fortschr. Med. Nr.III , 1–5 (2005).
   Google Scholar
• Lötsch J . Opioid metabolites. J. Pain Symptom Manage.29(5 Suppl.) , S10–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Hagen N , ThirlwellMP, DhaliwalHS, BabulN, HarsanyiZ, DarkeAC. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J. Clin. Pharmacol.35 , 37–44 (1995).
   PubMed Web of Science ®Google Scholar
• Parab PV , RitschelWA, CoyleDE, GreggRV, DensonDD. Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. Biopharm. Drug Dispos.9 , 187–199 (1988).
   PubMed Web of Science ®Google Scholar
• Chang AK , BijurPE, MeyerRH, KennyMK, SolorzanoC, GallagherEJ. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial. Ann. Emerg. Med.48 , 164–172 (2006).
   PubMed Web of Science ®Google Scholar
• Wallace M , RauckRL, MoulinD, ThipphawongJ, KhannaS, TudorIC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J. Int. Med. Res.36 , 343–352 (2008).
   PubMed Web of Science ®Google Scholar
• Vallner JJ , StewartJT, KotzanJA, KirstenEB, HonigbergIL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J. Clin. Pharmacol.21 , 152–156 (1981).
   PubMed Web of Science ®Google Scholar
• Vashi V , HarrisS, El-TahtawyA, WuD, CiprianoA. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules. J. Clin. Pharmacol.45 , 547–554 (2005).
   PubMed Web of Science ®Google Scholar
• Moulin DE , KreeftJH, Murray-ParsonsN, BouquillonAI. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet337 , 465–468 (1991).
   PubMed Web of Science ®Google Scholar
• Clemens K , KlaschikE. Clinical experience with transdermal and orally administered opioids in palliative care patients – a retrospective study. Jpn J. Clin. Oncol.37 , 302–309 (2007).
   PubMed Web of Science ®Google Scholar
• Clemens K , KlaschikE. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J. Pain Symptom Manage.33 , 473–481 (2007).
   PubMed Web of Science ®Google Scholar
• Babul N , DarkeAC, HainR. Hydromorphone and metabolite pharmacokinetics in children. J. Pain Symptom Manage.10 , 335–337 (1995).
   PubMed Web of Science ®Google Scholar
• Quigley C . Hydromorphone for acute and chronic pain. Cochrane Database Syst. Rev.1 , CD003447 (2002).
   Google Scholar
• Felden L , WalterC, HarderS et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br. J. Anaesth. 107(3) , 319–328 (2011).
   PubMed Web of Science ®Google Scholar
• Palladon® 1.3 mg/2.6 mg prescribing information. Mundipharma GmbH, Limburg, Germany (2012).
   Google Scholar
• Hanna M , Thipphawong J; 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat. Care7 , 17 (2008).
   PubMedGoogle Scholar
• Hagen NA , BabulN. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer79 , 1428–1437 (1997).
   PubMed Web of Science ®Google Scholar
• Hays H , HagenN, ThirlwellM et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 74 , 1808–1816 (1994).
   PubMed Web of Science ®Google Scholar
• Bruera E , SloanP, MountB, ScottJ, Suarez-AlmazorM. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian palliative care clinical trials group. J. Clin. Oncol.14 , 1713–1717 (1996).
   PubMed Web of Science ®Google Scholar
• Eychmüller Steffen. Die Qual der Wahl bei der Therapie mit stark wirksamen Opioiden. Primary Care4 , 561–564 (2004).
   Google Scholar
• Chaplan SR , DuncanSR, BrodskyJB, BroseWG. Morphine and hydromorphone epidural analgesia. A prospective, randomized comparison. Anesthesiology77 , 1090–1094 (1992).
   PubMed Web of Science ®Google Scholar
• Deer TR , PragerJ, LevyR et al. Polyanalgesic Consensus Conference-2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 15(5) , 420–435 (2012).
   PubMed Web of Science ®Google Scholar
• Clemens K , KlaschikE, FaustM. Efficacy and safety of immediate-release hydromorphone for the management of breakthrough pain in palliative care patients with cancer pain. Presented at: 7th Congress of the European Federation of IASP Chapters. Hamburg, Germany, 21–24 September 2011 (Abstract 84).
   Google Scholar
• Clemens K , FaustM. Efficacy and intake frequency of immediate-release hydromorphone vs oral transmucosal fentanyl citrate for the management of breakthrough cancer pain in palliative care patients. Presented at: 14th World Congress on Pain. Milan, Italy, 27–31 August 2012 (PT 383).
   Google Scholar
• Ahrens P , BerndtG, SchererS, LeunerC. Applikation von Palladon® Retard oder Palladon 1.3/2.6 mg via PEG-Sonde. Presented at: Der Deutsche Schmerz- und Palliativtag. Frankfurt, Germany, 26–28 March 2009.
   Google Scholar
• Miller MG , McCarthyN, O‘BoyleCA, KearneyM. Continuous subcutaneous infusion of morphine vs hydromorphone: a controlled trial. J. Pain Symptom Manage.18 , 9–16 (1999).
   PubMed Web of Science ®Google Scholar
• Chang AK , BijurPE, DavittM, GallagherEJ. Randomized clinical trial comparing a patient-driven titration protocol of intravenous hydromorphone with traditional physician-driven management of emergency department patients with acute severe pain. Ann. Emerg. Med.54 , 561–567.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Palladon® inject 2 mg/10 mg/100 mg prescribing information. Mundipharma GmbH, Limburg, Germany (2011).
   Google Scholar
• Dunbar PJ , ChapmanCR, BuckleyFP, GavrinJR. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain68 , 265–270 (1996).
   PubMed Web of Science ®Google Scholar
• Du Pen S , Du Pen A, Hillyer J. Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study. Pain Med.7 , 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Searle NR , RoyM, BergeronG et al. Hydromorphone patient-controlled analgesia (PCA) after coronary artery bypass surgery. Can. J. Anaesth. 41 , 198–205 (1994).
   PubMed Web of Science ®Google Scholar
• Hong D , FloodP, DiazG. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth. Analg.107 , 1384–1389 (2008).
   PubMed Web of Science ®Google Scholar
• Rapp SE , EganKJ, RossBK, WildLM, TermanGW, ChingJM. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesth. Analg.82 , 1043–1048 (1996).
   PubMed Web of Science ®Google Scholar

▪ Websites

• WHO. Scoping Document for WHO treatment guideline on non-malignant pain in adults. Adopted in WHO Steering Group on Pain Guidelines, 14 October 2008. www.who.int/medicines/areas/quality_safety/Scoping_WHOGuide_non-malignant_pain_adults.pdf (Accessed 18August2011)
   Google Scholar
• WHO. Scoping document for WHO treatment guideline on pain related to cancer, HIV and other progressive life-threatening illnesses in adults. Adopted in WHO Steering Group on Pain Guidelines, 14 October 2008. www.who.int/medicines/areas/quality_safety/Scoping_WHOGuide_malignant_pain_adults.pdf (Accessed 18August2011)
   Google Scholar